The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: MethylGene Inc.

Monday Deal Review: November 26, 2012

Welcome to your Monday Biotech Deal Review for November 26, 2012. This past week saw Valeant continue their aggressive stock repurchase program. Valeant plans to repurchase up to $1.5 billion worth of its own stock, senior notes or debt. Further, we saw Paladin expand its potential sales reach with the purchase of a controlling stake in Mexico-based Ativa Pharma.  Get the full breakdown of these and many more of the past week’s major biotech stories.   
Read more of this post

Monday Deal Review: November 19, 2012

Welcome to your Monday Biotech Deal Review for November 19, 2012. This past week saw the FTC give Valeant formal approval to acquire Medicis. A busy week on the investment front saw Kane Biotech, Lignol and MethylGene announce their intentions to raise capital. We also saw Abattis executing their previously announced licensing agreement with Vertical Design Systems for the use of Vertical’s plants, plant materials and extracts production technology. For more details on these sotries as well as many more, click through below!  
Read more of this post

Monday Biotech Deal Review: July 5, 2010

Not a bad week for deals, considering the holiday weekend in both Canada and the U.S.. Response Biomedical placed a PIPE with OrbiMed funds, CTI did a follow-on round in Zymeworks and LAB Research took an equity line. Plus a companion diagnostic deal from Aeterna, just as I’m planning for Diagnostics Asia in August. The week’s rounded out with $450k from the NRC and a spin-out from Ondine. Read more of this post

Monday Biotech Deal Review: May 24, 2010

The lead up to the long weekend here in Canada (Victoria Day, in case you’re wondering where we all went) saw only one new financing and two new commercial deals. A few more deals that were launched earlier closed this week, including MethylGene’s SR&ED financing; but stay tuned for an uptick next week as we move fully out of earnings reporting doldrums. In the meantime…

Read more of this post

Monday Biotech Deal Review: May 17, 2010

Lots of quarterly earnings announcements this week means a dip in deal activity. Still plenty of interesting stuff, though, including a new partnership and new listing plans for Tekmira. Meanwhile, for Medicago it’s graduation day, with a $10m present standby deal from Mom and Dad Yorkville Advisors on offer as it takes its symbol to the TSX big board from the venture exchange.

Read more of this post

Monday Biotech Deal Review: March 29, 2010

This week’s Canadian biotech deals include an acquisition by Biovail, Hæmacure’s BIA filing comes to a predictable end, MethylGene finds $8.9 million in its couch cushions from some Ontario numbered corps, Leap Medical leaps ahead with $1 million from MSBiV and other Quebec favourites, and BioSyntech borrows against its SR&EDs.  Those, plus more securities, debt and commercial deals after the jump…

Monday Biotech Deal Review: October 18, 2009

B&W_BigNickelThis week’s deal review has a big bought deal for IMRIS (and RBC), the details of Cardiome’s successful offer, and some follow-through for MethylGene and BioSyntech.  Read more of this post

Monday Biotech Deal Review: September 14, 2009

B&W_BigNickelThe Monday Deal Review is back in full force this week following a Labo(u)r Day vacation last week and there’s plenty of news including more information on the MDS-Danaher transaction and plenty of other companies finding ways to raise money and keep the lights on.  Keep reading after the jump…


Get every new post delivered to your Inbox.

Join 130 other followers